AICentralResources
AI Tool Comparison

Comparing as AI Medical Research & Clinical Decision Support
PathAI vs DAX Copilot

PathAI

PathAI

VS
DAX Copilot

DAX Copilot

Verdict by Category

Detailed category analysis is not available for this comparison.
View PathAI View DAX Copilot

Detailed Comparison

Feature
PathAI
DAX Copilot
Pricing
EnterprisePathAI operates exclusively on enterprise contracts with hospitals, pathology labs, and biopharma companies — there is no published pricing or self-serve access. Following its acquisition by Roche in May 2026, PathAI's commercial and contract terms are managed through Roche's diagnostics division. Clinical lab engagements use AISight for digital pathology workflow integration and AI algorithm deployment. Biopharma partnerships are structured as research service contracts for clinical trial tissue analysis, biomarker discovery, and companion diagnostic development. Contact PathAI or Roche Diagnostics to explore enterprise and research partnership options.
CustomMicrosoft does not publish self-serve pricing for DAX Copilot / Dragon Copilot; access is sold through Microsoft sales or authorized Cloud Solution Provider resellers, and pricing has varied significantly by channel and date. For years, authorized resellers commonly quoted $369-$830+ per provider per month plus a one-time setup fee (often around $650-$700), depending on contract size and minimum term. In a May 2026 marketplace restructuring, Microsoft published tiered list pricing including a Flex plan at roughly $604.80 per user per month (base license plus pay-as-you-go ambient use) and a higher uncapped Per-User tier around $1,512 per user per month (itself a 57% cut from a prior list price). A lower-cost "Physician Practice" license aimed at 5-50 clinician offices was briefly offered via the CSP channel at roughly $150-$160 per user per month before reaching end-of-sale on May 1, 2026. Large health systems negotiating volume, multi-year contracts frequently report effective rates well below these list prices. There is no public free trial for individual purchase, though Microsoft runs structured 30-90 day enterprise pilot programs for qualifying health systems.
Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Productivity ToolsAI Developer APIs & Platforms
Summary
AI-powered digital pathology platform for oncology diagnostics and biopharma R&D — now part of Roche
Microsoft's enterprise ambient AI for physicians, nurses, and radiologists — formerly Nuance DAX
PathAI

PathAI Pros & Cons

Pros

  • Acquired by Roche (May 2026) — now backed by the world's largest diagnostics company
  • 32.5M+ expert annotations — one of the world's largest pathology AI training datasets
  • 20+ AI algorithms covering oncology, liver disease, and tumor microenvironment analysis
  • AISight is scanner-neutral — works with Leica, Hamamatsu, Philips scanners with FDA clearance
  • CLIA-certified lab services for biopharma clinical trial support
  • Partnerships with BMS, Merck, Moffitt Cancer Center, and University Hospital Zurich
  • First AI pathology company recognized as a leader in CB Insights Digital Pathology market map

Cons

  • Acquired by Roche in May 2026 — future product roadmap and independent operations may change
  • Enterprise and biopharma-focused — not accessible to independent pathologists or small labs
  • No self-serve pricing or trial — all engagements are through enterprise procurement
  • Requires digital pathology infrastructure (scanners, storage, LIS integration)
  • Integration complexity for labs not yet on digital pathology workflows
DAX Copilot

DAX Copilot Pros & Cons

Pros

  • Broadest role coverage of any major ambient AI platform, spanning physicians, nurses, and radiologists in one product family
  • Deepest, longest-running Epic integration in the category, built on two decades of Dragon speech technology
  • Backed by Microsoft's security, compliance (HITRUST, SOC 2 Type II), and Azure infrastructure at massive scale
  • Extensible via a Developer Kit and third-party app marketplace rather than a closed, single-vendor tool
  • Strong, publicly documented customer outcomes (time-in-note reductions, added appointments) across large health systems
  • Available across multiple countries for physicians, with continued regional expansion

Cons

  • No public pricing; buyers must go through Microsoft sales or a reseller, and quoted rates vary enormously (roughly $150 to $1,500+ per provider per month across sources)
  • No self-serve signup or public free trial, unlike most consumer-facing AI scribes; enterprise procurement is required even for small practices
  • Historically the most expensive mainstream ambient scribe, which prices out solo clinicians and small independent practices
  • EHR write-back connectors for non-Epic systems are sometimes a separate, additional cost arranged through third-party partners
  • Nurse and radiologist experiences have more limited geographic availability (US-only, with radiology still in preview) than the physician product